Chemical Compound Review:
Cadraten ethylN-[[6-(ethyl-(2- hydroxypropyl)amino)...
Synonyms:
Cadrilan, Cadralazina, cadralazine, Cadralazinum, SureCN48939, ...
- Effect of cadralazine on brachial artery hemodynamics and forearm venous tone in essential hypertension. Bouthier, J.A., Safar, M.E., Curien, N.D., London, G.M., Levenson, J.A., Simon, A.C. Clin. Pharmacol. Ther. (1986)
- Cadralazine challenge in patients with previous hydralazine-induced lupus: a 6-month study. Pålsson, L., Weiner, L., Englund, G., Henning, M. Clin. Pharmacol. Ther. (1989)
- Cadralazine for the treatment of preeclampsia. An open, noncomparative, dose-finding pilot study. Voto, L.S., Lapidus, A.M., Catuzzi, P., Uranga Imaz, F., Zin, C., Margulies, M. Hypertension (1992)
- Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. McTavish, D., Young, R.A., Clissold, S.P. Drugs (1990)
- Hemodynamic effects of cadralazine or chlorthalidone in verapamil-treated elderly hypertensives. Antonicelli, R., Savonitto, S., Tomassini, P.F., Gambini, C., Sardina, M., Paciaroni, E. International journal of clinical pharmacology and therapeutics. (1994)
- Hemodynamics of the carotid artery after vasodilation in essential hypertension. Laurent, S., Lacolley, P., London, G., Safar, M. Hypertension (1988)
- Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension. Catalano, M., Parini, J., Romano, M., Libretti, A. Eur. J. Clin. Pharmacol. (1985)
- Carotid arterial hemodynamics in hypertension: acute administration of captopril or cadralazine. Lacolley, P.J., Laurent, S.T., Billaud, E.B., Safar, M.E. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. (1989)
- Different effects of temocapril and cadralazine on electrocardiographic voltages and left ventricular mass in patients with essential hypertension. Tomita, S., Takata, M., Yasumoto, K., Tomoda, F., Ueno, H., Inoue, H. Japanese heart journal. (1999)
- Pharmacokinetics of cadralazine in a large group of hypertensive patients chronically treated with cadralazine: advantage over a conventional study in a small group of patients. Lecaillon, J.B., Dubois, J.P., Darragon, T., Motolese, M., Racine, A., Ducret, F., Grouberman, D., Cordonnier, D., Chanard, J., Glorioso, M. Therapeutic drug monitoring. (1991)
- Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects. Brunel, P., Lecaillon, J.B., Guyene, T.T., Imhof, P., Ménard, J. British journal of clinical pharmacology. (1990)
- Hemorheologic effects of vasodilation in essential hypertension. Wysocki, M., Andersson, O.K., Persson, B., Bagge, U., Braide, M. Angiology. (1996)
- Hemodynamic effects of cadralazine in hexamethonium treated and non-treated anesthetized dogs. Higashio, T., Tsuji, Y., Nakao, K., Sakaguchi, S., Tanaka, M. Arzneimittel-Forschung. (1988)
- Inhibitory effects of cadralazine and its metabolite, ISF-2405, on contractions and the level of cytosolic Ca2+ in vascular smooth muscle. Mitsui, M., Nakao, K., Inukai, T., Karaki, H. Eur. J. Pharmacol. (1990)
- Pharmacokinetics of an active cadralazine metabolite in plasma and blood vessels of spontaneously hypertensive rats. Terauchi, Y., Watari, S., Ishikawa, S., Takeyama, K., Sekine, Y., Hashimoto, M., Hayashi, T. Arzneimittel-Forschung. (1988)
- Role of an intact endothelium in the vascular action of cadralazine and ISF2405. Buccellati, C., Dorigotti, L., Lombroso, M., Folco, G. Pharmacol. Res. (1989)
- Drug induced acute generalized exanthematous pustulosis. Katagiri, K., Takayasu, S. J. Dermatol. (1996)
- Synthesis and biotransformation of 3-hydrazinopyridazine drugs. Pinza, M., Pifferi, G. Farmaco (1994)
- Cadralazine and chlorthalidone as a second-step drug with atenolol in hypertensive patients: differences in blood pressure control during exercise. Costa, F.V., Borghi, C., Mussi, A., Ambrosioni, E. Eur. J. Clin. Pharmacol. (1986)
- Cadralazine versus prazosin as second-step treatment in hypertensive patients on beta-blockers: a randomized multicentre study. The Italian Multicentre Study Group. Caponnetto, S., Valvo, E., Mocarelli, P., Alberti, D., Savonitto, S. Eur. J. Clin. Pharmacol. (1991)
- The antihypertensive compounds hydralazine, dihydralazine and cadralazine and their metabolites inhibit myeloperoxidase activity as measured by chemiluminescence. Nässberger, L. Biochem. Pharmacol. (1991)
- Effects of cadralazine on systemic blood pressure, renal function and plasma renin activity in anesthetized dogs. Yukimura, T., Miura, K., Tanaka, M., Higashio, T., Sakaguchi, S., Kuroda, K., Yamamoto, K. Arzneimittel-Forschung. (1988)
- Determination of cadralazine in human plasma and urine by high-performance liquid chromatography. Hauffe, S.A., Dubois, J.P. J. Chromatogr. (1984)
- Cadralazine (ISF 2469): dose-related antihypertensive activity after single oral administration to patients. Catalano, M., Parini, J., Libretti, A. Eur. J. Clin. Pharmacol. (1983)